当前位置: X-MOL 学术JAMA › 论文详情
Early Returns From the Era of Precision Medicine.
JAMA ( IF 45.540 ) Pub Date : 2020-01-14 , DOI: 10.1001/jama.2019.20659
David M Cutler

The era of precision medicine has arrived. A large share of new pharmaceuticals are tested and approved on the basis of biomarkers. Pharmacogenetics—the tailoring of drugs to patients based on 1 or more biomarkers—is used in conditions as diverse as HIV and thromboembolism.

Precision medicine raises hopes for patients and fears for those who try to ride herd on health care spending. Will patients finally live longer and healthier lives? Will society be able to afford it? Surprisingly, at this point, personalized medicine has had less effect on both health and medical spending than either its strongest backers hoped or its most apprehensive actuaries feared.

Oncology has been the primary focus of precision medicine. One recent analysis by the IQVIA Institute found that 97 new anticancer medications have been approved since 2011. A 2018 study published in JAMA Oncology found that 31 genome-targeted or genome-informed anticancer drugs were in use as of January 2018.

更新日期:2020-01-14

 

全部期刊列表>>
施普林格自然
最近合集,配们化学
欢迎访问IOP中国网站
GIANT
自然职场线上招聘会
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
何川
苏昭铭
陈刚
姜涛
李闯创
复旦大学
刘立明
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
上海纽约大学
曾林
天津大学
何振宇
史大永
吉林大学
卓春祥
张昊
刘冬生
试剂库存
down
wechat
bug